Previous 10 | Next 10 |
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2019 financial results after the U.S. financial markets close on Thursday, November 7, 2019. Oncter...
Gainers: NF Energy Saving (NASDAQ: BIMI ) +286% . Synthesis Energy Systems (NASDAQ: SES ) +156% . Yuma Energy (NYSEMKT: YUMA ) +58% . Ideal Power (NASDAQ: IPWR ) +34% . Oncternal Therapeutics (NASDAQ: ONCT ) +31% . Bio-Path Holdings (NASDAQ: BPTH ) +21% . Enochian Biosciences (NASDA...
Oncternal Therapeutics ( ONCT ) may be a good speculative biotech to look into. That's because it has been able to develop a monoclonal antibody, known as cirmtuzumab, which targets the ROR1 protein. The targeting of this ROR1 protein allows cirmtuzumab to be explored in a couple of other comb...
Cirmtuzumab combination demonstrated clinical activity with complete responses in mantle cell lymphoma Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has opened for ...
Sustained objective response reported for patient with challenging pediatric cancer Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Paul A. Meyers, M.D., Chief, Pediatri...
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, P...
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., a...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a tumultuous week, dipping from 3,330.51 points on Monday (August 19) to 3,257.94 points at 12:22 p.m. EDT on Friday (August 23). On Monday, Nabriva (NASDAQ: NBRV ) notched its first approval from the US Food and Drug Administration (F...
Gainers : DPW Holdings, Inc. (NYSEMKT: DPW ) +217% . Yuma Energy (NYSEMKT: YUMA ) +210% . DryShips (NASDAQ: DRYS ) +35%. TrovaGene (NASDAQ: TROV ) +32% . Qiwi (NASDAQ: QIWI ) +22% . Houston Wire & Cable (NASDAQ: HWCC ) +22%. China Green Agriculture (NYSE: CGA ) +21%....
Oncternal Therapeutics, Inc. (ONCT) Q2 2019 Results Earnings Conference Call August 08, 2019, 05:00 PM ET Company Participants Richard Vincent - Chief Financial Officer James Breitmeyer - President and CEO Conference Call Participants Hartaj Singh - Oppenheimer Kumar Raja -...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets c...
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...